Dr Hanan Al Suwaidi’s 3 roles put training pressure on UAE clinics and pharmacies

Dr Hanan Al Suwaidi, profiled by Emirates 24|7, now sits at the junction of medicine, education and system leadership as Deputy CEO of Dubai Health, Chief Academic Officer of Dubai Health and Provost of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU).

The readers with the most at stake are COOs, HR leaders and medical directors. For clinics and pharmacy operators in Dubai, the practical point is that workforce training is part of licence renewal, clinical risk and patient trust. Dubai Health Authority (DHA) regulates Dubai providers, Department of Health Abu Dhabi (DOH) regulates Abu Dhabi and Al Ain, and Ministry of Health and Prevention (MOHAP) regulates federal health services and much of the northern emirates.

Why this profile matters to operators

Emirates 24|7 frames Dr Al Suwaidi’s career as a shift from proving presence to creating impact in medicine, education and leadership. The official Dubai Health executive leadership page lists her three current roles. That makes the story more than a personal profile. It signals how Dubai’s academic health system is linking clinical practice, medical education and research governance.

For clinic owners, the signal is workforce quality. For pharmacy groups, it is the same issue in a lower-margin setting. Pharmacists are patient-facing clinicians in chronic disease adherence, prescription counselling and adverse-event escalation. A pharmacy that cannot prove staff competence is exposed when insurers, regulators or patients question dispensing quality.

DHA’s Sheryan service states that healthcare professionals must manage and update CPD points required to maintain a full-time licence, with targets based on professional category and licence validity. DHA’s professional renewal prerequisites also include valid malpractice insurance, minimum annual CME or CPD requirements and payment of outstanding fines where applicable.

What clinics, insurers and pharmacies should check

Dr Al Suwaidi’s leadership role matters because education is now a compliance input. On 16 July 2026, MBRU said it had become an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education. MBRU said it can independently award AMA PRA Category 1 Credits, a CME measure accepted in more than 40 countries.

Operators should convert that into three checks before the next renewal cycle:

• Confirm each clinician and pharmacist has an active DHA, DOH or MOHAP licence in the emirate where they practise.
• Keep CPD and CME evidence in the staff file, with certificate dates matched to the licence period.
• Ask insurers such as Daman, Thiqa and Sukoon how credentialing gaps affect claims approval, network status and audit findings.
• Review pharmacy counselling workflows for high-risk medicines, including anticoagulants, insulin and controlled drugs.

Patients will see the effect in access and out-of-pocket cost. For common generic medicines in Dubai, Zavis directory listings typically show entry-level prices around AED 10 to AED 50, before insurance terms, branded substitutions or dispensing restrictions. The price that matters is the confirmed counter price after the pharmacy checks the patient’s plan, co-pay and prior-approval status.

The wider UAE angle

Dubai is the first market to watch because Dubai Health and MBRU are local institutions, and DHA licensing systems are public-facing. Abu Dhabi operators should read the same story through DOH’s Shafafiya infrastructure, which includes dictionaries for insurers, clinicians, facilities, facility licensing history and coding-certified facilities. Northern emirates operators should check MOHAP directories and licence status before cross-emirate recruitment.

The insurance angle is direct. If better-trained clinicians reduce medication errors, repeat consultations and avoidable emergency visits, payers have a financial reason to prefer networks with auditable training records. If training remains a paper exercise, claims teams will keep using audits and pre-authorisation rules as cost controls.

For patients, the practical test is simple. Ask whether the pharmacy is licensed, whether the dispensing pharmacist is present, whether insurance is accepted for the specific medicine, and whether a cheaper generic is available. Providers should make those answers routine, since patients can compare licensed pharmacy providers through the UAE Open Healthcare Directory.